Title : Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.

Pub. Date : 2014 Oct

PMID : 25379021






7 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. AZD 6244 ribosomal protein S6 kinase B1 Homo sapiens
2 Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. AZD 6244 ribosomal protein S6 kinase B1 Homo sapiens
3 Surprisingly, Selumetinib was able to inhibit phosphorylation of p70 S6 kinase (p70S6K) and its downstream target ribosomal protein S6 (RPS6) in sensitive cell lines. AZD 6244 ribosomal protein S6 kinase B1 Homo sapiens
4 Surprisingly, Selumetinib was able to inhibit phosphorylation of p70 S6 kinase (p70S6K) and its downstream target ribosomal protein S6 (RPS6) in sensitive cell lines. AZD 6244 ribosomal protein S6 kinase B1 Homo sapiens
5 Pharmacological inhibition of p70S6K using the PI3K/mTOR inhibitor NVP-BEZ235, the specific mTOR inhibitor Rapamycin and the specific p70S6K inhibitor PF-4708671 potentiated Selumetinib effects in resistant cells. AZD 6244 ribosomal protein S6 kinase B1 Homo sapiens
6 In addition, biological inhibition of p70S6K using siRNA rendered responsiveness to Selumetinib in resistant cell lines. AZD 6244 ribosomal protein S6 kinase B1 Homo sapiens
7 We can conclude that p70S6K and its downstream target RPS6 are potential biomarkers of resistance to Selumetinib in colorectal cancer. AZD 6244 ribosomal protein S6 kinase B1 Homo sapiens